Publications

1. International agenda

   The international agenda describes the work of the National Health Care Institute in the international field. We collaborate with ...

   Report | 01-03-2024

2. Advice - Early discontinuation of conditional inclusion of medicinal products rhPTH 1-84 (Natpar®) and ataluren (Translarna®)

   The National Health Care Institute advises the Minister for Medical Care to discontinue the conditional inclusion of the ...

   Report | 21-02-2024

3. Advice - Extension of reimbursement conditions for solriamfetol (Sunosi®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the List 2 conditions ...

   Report | 16-02-2024

4. Package advice on the lock procedure medicinal product olaparib (Lynparza®) for the treatment of hereditary breast cancer

   The National Health Care Institute has assessed whether the medicinal product olaparib (Lynparza®) can be reimbursed from the ...

   Report | 13-02-2024

5. Guideline for economic evaluations in healthcare (2024 version)

   More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...

   Report | 16-01-2024

6. Advice - Reimburse voclosporin (Lupkynis®) for the treatment of rare kidney inflammation (lupus nephritis)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse voclosporin ...

   Report | 21-12-2023

7. Advice - Adjustment of reimbursement conditions for lenacapavir (Sunlenca®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to adjust the conditions of ...

   Report | 20-12-2023

8. Advice - Extension of reimbursement conditions for risdiplam (Evrysdi®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to also reimburse risdiplam ...

   Report | 20-12-2023

9. Package advice on the lock procedure medicinal product abemaciclib (Verzenios®) for the treatment of breast cancer

   The National Health Care Institute has assessed whether the medicinal product abemaciclib (Verzenios®) can be reimbursed as an ...

   Report | 13-12-2023

10. GVS advice reassessment migalastat (Galafold®) for the treatment of Fabry disease

    At the request of the Minister for Health, Welfare and Sport (VWS), the National Health Care Institute assessed whether ...

    Report | 13-12-2023